Overview

Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

This pilot study is designed as a prospective cohort study to determine whether standard subcutaneous (SQ) Highly-Purified (HP) Acthar Gel 14 days is superior to SQ HP Acthar Gel 5 days in the treatment of relapses or attacks in multiple sclerosis (MS).

Phase:

Phase 4

Details

Lead Sponsor:

The University of Texas Health Science Center, Houston

Treatments:

Adrenocorticotropic Hormone